Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $27.40 Consensus PT from Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been assigned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $27.40.

Several research firms have commented on KMTS. BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. Finally, The Goldman Sachs Group cut their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00. Following the completion of the transaction, the insider owned 349,786 shares in the company, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 45,000 shares of company stock valued at $988,650. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KMTS. Spartan Wealth Advisory Services LLC purchased a new position in Kestra Medical Technologies during the first quarter worth about $603,000. Bank of New York Mellon Corp increased its position in Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares during the period. Invesco Ltd. purchased a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $239,000. Perceptive Advisors LLC purchased a new position in shares of Kestra Medical Technologies during the 4th quarter worth approximately $7,558,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $300,000.

Kestra Medical Technologies Trading Up 3.7%

Shares of Kestra Medical Technologies stock opened at $21.83 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32. The company has a market capitalization of $1.27 billion, a P/E ratio of -5.51 and a beta of 0.82. Kestra Medical Technologies has a 1 year low of $13.25 and a 1 year high of $30.00. The company’s fifty day moving average is $20.86 and its two-hundred day moving average is $24.06.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business had revenue of $24.55 million during the quarter. Kestra Medical Technologies’s revenue was up 62.7% compared to the same quarter last year. Analysts forecast that Kestra Medical Technologies will post -2.34 earnings per share for the current year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.